---
title: "Shenyang Xingqi Pharmaceutical Co., Ltd. (300573.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300573.SZ.md"
symbol: "300573.SZ"
name: "Shenyang Xingqi Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T21:45:06.777Z"
locales:
  - [en](https://longbridge.com/en/quote/300573.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300573.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300573.SZ.md)
---

# Shenyang Xingqi Pharmaceutical Co., Ltd. (300573.SZ)

## Company Overview

Shenyang Xingqi Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of ophthalmic drugs in the People’s Republic of China. The company offers myopia prevention and control medications, nutrition and corneal repair drugs, ophthalmic anti-inflammatory and anti-infective drugs, artificial tears and eye lubricants, ophthalmic non-steroidal anti-inflammatory drugs, intraocular rinsing fluids, pupil dilatant and ciliary muscle paralyzers, anti-fatigue medicines, dry eye treatment medicines, mydriatics and cycloplegia drugs, miotics and anti-glaucoma drugs, and intraoperative intraocular irrigation fluids. It also engages in technology development, technical advice, eye hospital, and research and experimental development activities. Shenyang Xingqi Pharmaceutical Co.,Ltd.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.sinqi.com](https://www.sinqi.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: A
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: A (0.18)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 2 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: A

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 23.03% |  |
| Net Profit YoY | 68.38% |  |
| P/B Ratio | 7.52 |  |
| Dividend Ratio | 2.11% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 16466085765.65 |  |
| Revenue | 2624709275.57 |  |

#### Multi Score Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 38.51% | A |
| Profit Margin | 28.87% | A |
| Gross Margin | 82.05% | A |
| Revenue YoY | 23.03% | A |
| Net Profit YoY | 68.38% | A |
| Total Assets YoY | 19.69% | A |
| Net Assets YoY | 25.35% | A |
| Cash Flow Margin | 101.96% | C |
| OCF YoY | 23.03% | A |
| Turnover | 1.04 | A |
| Gearing Ratio | 20.51% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shenyang Xingqi Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "23.03%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "68.38%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "7.52",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.11%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "16466085765.65",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2624709275.57",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "38.51%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "28.87%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "82.05%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "23.03%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "68.38%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "19.69%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "25.35%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "101.96%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "23.03%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "1.04",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "20.51%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 21.31 | 52/215 | 32.81 | 28.22 | 26.21 |
| PB | 7.38 | 203/215 | 9.68 | 9.08 | 7.84 |
| PS (TTM) | 6.15 | 144/215 | 7.60 | 7.18 | 6.52 |
| Dividend Yield | 2.15% | 62/215 | 2.07% | 1.99% | 1.82% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300573.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300573.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300573.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300573.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**